Asset
DUSQUETIDE
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02013050 | phase2 | completed | 2013-12-01 | 2015-12-01 | Soligenix | A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer |
| NCT03237325 | phase3 | completed | 2017-12-04 | 2020-06-24 | Soligenix | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer |
| NCT06386744 | phase2 | completed | 2024-11-18 | 2025-05-23 | Soligenix | Dusquetide for the Treatment of Behcet's Disease |
FDA applications (0)
This company has no applications containing this asset.